President and Interim Chief executive OfficeR
Over 20 years in the Manufacturing, Media and Financial Services industries in senior roles.
Over 10 years with the Financial Post and National Post newspapers.
Bachelor of Business Administration from Bishop’s University
Chief Financial Officer and director
Chief Operating Officer
Senior Vice President Investor Relations an Strategy for Australis Capital Inc.
Mr. Reuter has held positions as principal investor relations for Onex Corp., a private equity firm, vice-president of asset management for Canadian Imperial Bank of Commerce and as managing director at Royal Bank of Canada with roles in Hong Kong and New York. In these roles, he built high-value client and strategic partnerships, recruited and developed sales teams, and implemented and executed high-impact revenue coverage models.
Appointed to the Board of Body and Mind pursuant to nominee rights granted to Australis pursuant to its strategic investment into Body and Mind.
Mr. Wenger is an accomplished lawyer and for 13 years he represented foreign government and major corporate clients in high-stakes complex cross-border disputes and transactions.
Member of the US Senate Cannabis Working Group and the US House of Representatives Cannabis Working Group. In those roles, he has the historic opportunity to work with senior Congressional staffers on advancing federal cannabis legislation.
Mr. Wenger wrote a seminal White Paper on the US cannabis industry widely read across the world: The Green Regulatory Arbitrage: A Case for Investing in US Multi-State Vertically-Integrated Cannabis Companies.
Managing Director, Sperry Van Ness, a NV commercial real estate brokerage firm..
Involved in the origination and
syndication of more than $1b of commercial real estate acquisitions.
Over 10 years of experience in
business development and
Pioneer in the Nevada MJ market.
Bachelor of Arts, Ohio State University.
Founder and former CEO of Catalyst RX, a pharmacy benefit manager.
In 2001, Catalyst RX went public on Nasdaq under CRTX.
By 2012, CHSI revenues exceeded USD $5B and the company joined Fortune 500.
Later in 2012, the company achieved over $5B in sales and was sold for USD $4.4B.
Bachelor of science, Ohio State University.
Board certified pharmacist.